Patient-controlled subcutaneous analgesia with hydromorphone in cancer pain management

PCSA with hydromorphone hydrochloride injection offers significant therapeutic benefits for refractory cancer pain. It effectively reduces pain intensity, decreases opioid dosage, mitigates certain adverse reactions, and is associated with reduced anxiety and depression as well as improved sleep quality.

Institutions

Hebei Medical University (CN)
Fourth Hospital of Hebei Medical University (CN)

Publication Details

Journal: Frontiers in Pain Research
Published: 2025-12-17
DOI: https://doi.org/10.3389/fpain.2025.1674672
Primary Topic: Pain Management and Opioid Use
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Patient-controlled subcutaneous analgesia with hydromorphone in cancer pain management

Dec 17, 2025

Frontiers in Pain Research

Pain Management and Opioid Use

article

Patient-controlled subcutaneous analgesia with hydromorphone in cancer pain management

December 17, 2025article en

Abstract

Frontiers in Pain ResearchVol. 6

Hebei Medical University (CN), Fourth Hospital of Hebei Medical University (CN)

Good health and well-being

Openalex Percentile: Top 27%

Pain Management and Opioid Use

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Patient-controlled subcutaneous analgesia with hydromorphone in cancer pain management · Frontiers in Pain Research (2025) | TGRS Research Map | TGRS